LLY:NYSE

Eli Lilly posted a staggering 42.6% revenue growth and maintains an 83% gross margin, underscoring the strength of its obesity and diabetes franchise. Operating margins of 45% and a forward EPS of $41.96 point to a highly profitable business model, while a forward P/E near 24 suggests earnings are accelerating. However, the current trailing P/E of 43.5 and a DCF‑derived fair value of roughly $42 per share highlight a substantial valuation gap, implying the stock is significantly overvalued. Technical signals are mixed: the price sits below its 20‑day SMA, the MACD is bearish, RSI hovers around 45, and volume is on a downtrend, all of which temper short‑term enthusiasm. Volatility remains elevated at over 48% 30‑day and the beta is modest, indicating market swings can be sharp despite limited systematic risk. Analyst sentiment stays positive, with a consensus “Buy” and target prices near $1,250, driven by continued demand for GLP‑1 therapies and a robust pipeline.
The dividend appears sustainable, supported by a 26% payout ratio and strong operating cash flow, while the company’s low currency exposure and ample liquidity reduce financial strain. Yet, regulatory headwinds and intensifying competition in the obesity drug market introduce notable risk. Investors should weigh the high growth trajectory against the pronounced valuation premium and consider a phased approach to exposure.